O	0	3	The
B-intervention	4	10	cyclin
I-intervention	10	11	-
I-intervention	11	20	dependent
I-intervention	21	27	kinase
I-intervention	28	29	4
I-intervention	29	30	/
I-intervention	30	31	6
I-intervention	32	41	inhibitor
I-intervention	42	53	palbociclib
I-intervention	54	56	in
I-intervention	57	68	combination
I-intervention	69	73	with
I-intervention	74	83	letrozole
O	84	90	versus
B-control	91	100	letrozole
I-control	101	106	alone
O	107	109	as
O	110	115	first
O	115	116	-
O	116	120	line
O	121	130	treatment
O	131	133	of
O	134	143	oestrogen
O	144	152	receptor
O	152	153	-
O	153	161	positive
O	161	162	,
O	163	167	HER2
O	167	168	-
O	168	176	negative
O	176	177	,
O	178	186	advanced
O	187	193	breast
O	194	200	cancer
O	201	202	(
O	202	208	PALOMA
O	208	209	-
O	209	210	1
O	210	211	/
O	211	215	TRIO
O	215	216	-
O	216	218	18
O	218	219	)
O	219	220	:
O	221	222	a
O	223	233	randomised
O	234	239	phase
O	240	241	2
O	242	247	study
O	247	248	.

O	249	260	Palbociclib
O	261	262	(
O	262	264	PD
O	264	265	-
O	265	272	0332991
O	272	273	)
O	274	276	is
O	277	279	an
O	280	284	oral
O	284	285	,
O	286	291	small
O	291	292	-
O	292	300	molecule
O	301	310	inhibitor
O	311	313	of
O	314	320	cyclin
O	320	321	-
O	321	330	dependent
O	331	338	kinases
O	339	340	(
O	340	344	CDKs
O	344	345	)
O	346	347	4
O	348	351	and
O	352	353	6
O	354	358	with
O	359	370	preclinical
O	371	379	evidence
O	380	382	of
O	383	389	growth
O	389	390	-
O	390	400	inhibitory
O	401	409	activity
O	410	412	in
O	413	422	oestrogen
O	423	431	receptor
O	431	432	-
O	432	440	positive
O	441	447	breast
O	448	454	cancer
O	455	460	cells
O	461	464	and
O	465	472	synergy
O	473	477	with
O	478	482	anti
O	482	483	-
O	483	493	oestrogens
O	493	494	.

O	495	497	We
O	498	503	aimed
O	504	506	to
O	507	513	assess
O	514	517	the
O	518	524	safety
O	525	528	and
O	529	537	efficacy
O	538	540	of
O	541	552	palbociclib
O	553	555	in
O	556	567	combination
O	568	572	with
O	573	582	letrozole
O	583	585	as
O	586	591	first
O	591	592	-
O	592	596	line
O	597	606	treatment
O	607	609	of
B-eligibility	610	618	patients
I-eligibility	619	623	with
I-eligibility	624	632	advanced
I-eligibility	632	633	,
I-eligibility	634	643	oestrogen
I-eligibility	644	652	receptor
I-eligibility	652	653	-
I-eligibility	653	661	positive
I-eligibility	661	662	,
I-eligibility	663	667	HER2
I-eligibility	667	668	-
I-eligibility	668	676	negative
I-eligibility	677	683	breast
I-eligibility	684	690	cancer
O	690	691	.

O	692	694	In
O	695	699	this
O	700	704	open
O	704	705	-
O	705	710	label
O	710	711	,
O	712	722	randomised
O	723	728	phase
O	729	730	2
O	731	736	study
O	736	737	,
O	738	752	postmenopausal
O	753	758	women
O	759	763	with
O	764	772	advanced
O	773	782	oestrogen
O	783	791	receptor
O	791	792	-
O	792	800	positive
O	801	804	and
O	805	809	HER2
O	809	810	-
O	810	818	negative
O	819	825	breast
O	826	832	cancer
O	833	836	who
O	837	840	had
O	841	844	not
O	845	853	received
O	854	857	any
O	858	866	systemic
O	867	876	treatment
O	877	880	for
O	881	886	their
O	887	895	advanced
O	896	903	disease
O	904	908	were
O	909	917	eligible
O	918	920	to
O	921	932	participate
O	932	933	.

O	934	942	Patients
O	943	947	were
O	948	956	enrolled
O	957	959	in
O	960	963	two
O	964	972	separate
O	973	980	cohorts
O	981	985	that
O	986	993	accrued
O	994	1006	sequentially
O	1006	1007	:
O	1008	1010	in
O	1011	1017	cohort
O	1018	1019	1
O	1019	1020	,
O	1021	1029	patients
O	1030	1034	were
O	1035	1043	enrolled
O	1044	1046	on
O	1047	1050	the
O	1051	1056	basis
O	1057	1059	of
O	1060	1065	their
O	1066	1075	oestrogen
O	1076	1084	receptor
O	1084	1085	-
O	1085	1093	positive
O	1094	1097	and
O	1098	1102	HER2
O	1102	1103	-
O	1103	1111	negative
O	1112	1121	biomarker
O	1122	1128	status
O	1129	1134	alone
O	1134	1135	,
O	1136	1143	whereas
O	1144	1146	in
O	1147	1153	cohort
O	1154	1155	2
O	1156	1160	they
O	1161	1165	were
O	1166	1170	also
O	1171	1179	required
O	1180	1182	to
O	1183	1187	have
O	1188	1195	cancers
O	1196	1200	with
O	1201	1214	amplification
O	1215	1217	of
O	1218	1224	cyclin
O	1225	1227	D1
O	1228	1229	(
O	1229	1234	CCND1
O	1234	1235	)
O	1235	1236	,
O	1237	1241	loss
O	1242	1244	of
O	1245	1248	p16
O	1249	1250	(
O	1250	1255	INK4A
O	1256	1258	or
O	1259	1265	CDKN2A
O	1265	1266	)
O	1266	1267	,
O	1268	1270	or
O	1271	1275	both
O	1275	1276	.

O	1277	1279	In
O	1280	1284	both
O	1285	1292	cohorts
O	1292	1293	,
O	1294	1302	patients
O	1303	1307	were
O	1308	1316	randomly
O	1317	1325	assigned
O	1326	1327	1
O	1327	1328	:
O	1328	1329	1
O	1330	1333	via
O	1334	1336	an
O	1337	1348	interactive
O	1349	1352	web
O	1352	1353	-
O	1353	1358	based
O	1359	1372	randomisation
O	1373	1379	system
O	1379	1380	,
O	1381	1391	stratified
O	1392	1394	by
O	1395	1402	disease
O	1403	1407	site
O	1408	1411	and
O	1412	1419	disease
O	1419	1420	-
O	1420	1424	free
O	1425	1433	interval
O	1433	1434	,
O	1435	1437	to
O	1438	1445	receive
O	1446	1456	continuous
O	1457	1461	oral
O	1462	1471	letrozole
O	1472	1473	2
O	1473	1474	.
O	1474	1475	5
O	1476	1478	mg
O	1479	1484	daily
O	1485	1487	or
O	1488	1498	continuous
O	1499	1503	oral
O	1504	1513	letrozole
O	1514	1515	2
O	1515	1516	.
O	1516	1517	5
O	1518	1520	mg
O	1521	1526	daily
O	1527	1531	plus
O	1532	1536	oral
O	1537	1548	palbociclib
O	1549	1552	125
O	1553	1555	mg
O	1555	1556	,
O	1557	1562	given
O	1563	1567	once
O	1568	1573	daily
O	1574	1577	for
O	1578	1579	3
O	1580	1585	weeks
O	1586	1594	followed
O	1595	1597	by
O	1598	1599	1
O	1600	1604	week
O	1605	1608	off
O	1609	1613	over
O	1614	1616	28
O	1616	1617	-
O	1617	1620	day
O	1621	1627	cycles
O	1627	1628	.

O	1629	1632	The
O	1633	1640	primary
O	1641	1649	endpoint
O	1650	1653	was
O	1654	1666	investigator
O	1666	1667	-
O	1667	1675	assessed
B-outcome-Measure	1676	1687	progression
I-outcome-Measure	1687	1688	-
I-outcome-Measure	1688	1692	free
I-outcome-Measure	1693	1701	survival
O	1702	1704	in
O	1705	1708	the
O	1709	1718	intention
O	1718	1719	-
O	1719	1721	to
O	1721	1722	-
O	1722	1727	treat
O	1728	1738	population
O	1738	1739	.

O	1740	1747	Accrual
O	1748	1750	to
O	1751	1757	cohort
O	1758	1759	2
O	1760	1763	was
O	1764	1771	stopped
O	1772	1777	after
O	1778	1780	an
O	1781	1790	unplanned
O	1791	1798	interim
O	1799	1807	analysis
O	1808	1810	of
O	1811	1817	cohort
O	1818	1819	1
O	1820	1823	and
O	1824	1827	the
O	1828	1839	statistical
O	1840	1848	analysis
O	1849	1853	plan
O	1854	1857	for
O	1858	1861	the
O	1862	1869	primary
O	1870	1878	endpoint
O	1879	1882	was
O	1883	1890	amended
O	1891	1893	to
O	1894	1895	a
O	1896	1904	combined
O	1905	1913	analysis
O	1914	1916	of
O	1917	1924	cohorts
O	1925	1926	1
O	1927	1930	and
O	1931	1932	2
O	1933	1934	(
O	1934	1941	instead
O	1942	1944	of
O	1945	1951	cohort
O	1952	1953	2
O	1954	1959	alone
O	1959	1960	)
O	1960	1961	.

O	1962	1965	The
O	1966	1971	study
O	1972	1974	is
O	1975	1982	ongoing
O	1983	1986	but
O	1987	1993	closed
O	1994	1996	to
O	1997	2004	accrual
O	2004	2005	;
O	2006	2011	these
O	2012	2015	are
O	2016	2019	the
O	2020	2027	results
O	2028	2030	of
O	2031	2034	the
O	2035	2040	final
O	2041	2049	analysis
O	2050	2052	of
O	2053	2064	progression
O	2064	2065	-
O	2065	2069	free
O	2070	2078	survival
O	2078	2079	.

O	2080	2083	The
O	2084	2089	study
O	2090	2092	is
O	2093	2103	registered
O	2104	2108	with
O	2109	2112	the
O	2113	2127	ClinicalTrials
O	2127	2128	.
O	2129	2132	gov
O	2132	2133	,
O	2134	2140	number
O	2141	2152	NCT00721409
O	2152	2153	.

O	2154	2161	Between
O	2162	2165	Dec
O	2166	2168	22
O	2168	2169	,
O	2170	2174	2009
O	2174	2175	,
O	2176	2179	and
O	2180	2183	May
O	2184	2186	12
O	2186	2187	,
O	2188	2192	2012
O	2192	2193	,
O	2194	2196	we
O	2197	2205	randomly
O	2206	2214	assigned
B-total-participants	2215	2218	165
O	2219	2227	patients
O	2227	2228	,
B-intervention-participants	2229	2231	84
O	2232	2234	to
O	2235	2246	palbociclib
O	2247	2251	plus
O	2252	2261	letrozole
O	2262	2265	and
B-control-participants	2266	2268	81
O	2269	2271	to
O	2272	2281	letrozole
O	2282	2287	alone
O	2287	2288	.

O	2289	2291	At
O	2292	2295	the
O	2296	2300	time
O	2301	2303	of
O	2304	2307	the
O	2308	2313	final
O	2314	2322	analysis
O	2323	2326	for
B-outcome	2327	2338	progression
I-outcome	2338	2339	-
I-outcome	2339	2343	free
I-outcome	2344	2352	survival
O	2353	2354	(
O	2354	2360	median
O	2361	2367	follow
O	2367	2368	-
O	2368	2370	up
B-iv-cont-median	2371	2373	29
I-iv-cont-median	2373	2374	.
I-iv-cont-median	2374	2375	6
I-iv-cont-median	2376	2382	months
O	2383	2384	[
O	2384	2386	95
O	2386	2387	%
O	2388	2390	CI
O	2391	2393	27
O	2393	2394	.
O	2394	2395	9
O	2395	2396	-
O	2396	2398	36
O	2398	2399	.
O	2399	2400	0
O	2400	2401	]
O	2402	2405	for
O	2406	2409	the
O	2410	2421	palbociclib
O	2422	2426	plus
O	2427	2436	letrozole
O	2437	2442	group
O	2443	2446	and
B-cv-cont-median	2447	2449	27
I-cv-cont-median	2449	2450	.
I-cv-cont-median	2450	2451	9
I-cv-cont-median	2452	2458	months
O	2459	2460	[
O	2460	2462	25
O	2462	2463	.
O	2463	2464	5
O	2464	2465	-
O	2465	2467	31
O	2467	2468	.
O	2468	2469	1
O	2469	2470	]
O	2471	2474	for
O	2475	2478	the
O	2479	2488	letrozole
O	2489	2494	group
O	2494	2495	)
O	2495	2496	,
B-iv-bin-abs	2497	2499	41
B-outcome	2500	2511	progression
I-outcome	2511	2512	-
I-outcome	2512	2516	free
I-outcome	2517	2525	survival
I-outcome	2526	2532	events
O	2533	2536	had
O	2537	2545	occurred
O	2546	2548	in
O	2549	2552	the
O	2553	2564	palbociclib
O	2565	2569	plus
O	2570	2579	letrozole
O	2580	2585	group
O	2586	2589	and
B-cv-bin-abs	2590	2592	59
O	2593	2595	in
O	2596	2599	the
O	2600	2609	letrozole
O	2610	2615	group
O	2615	2616	.

B-outcome	2617	2623	Median
I-outcome	2624	2635	progression
I-outcome	2635	2636	-
I-outcome	2636	2640	free
I-outcome	2641	2649	survival
O	2650	2653	was
B-iv-cont-median	2654	2656	10
I-iv-cont-median	2656	2657	.
I-iv-cont-median	2657	2658	2
I-iv-cont-median	2659	2665	months
O	2666	2667	(
O	2667	2669	95
O	2669	2670	%
O	2671	2673	CI
O	2674	2675	5
O	2675	2676	.
O	2676	2677	7
O	2677	2678	-
O	2678	2680	12
O	2680	2681	.
O	2681	2682	6
O	2682	2683	)
O	2684	2687	for
O	2688	2691	the
O	2692	2701	letrozole
O	2702	2707	group
O	2708	2711	and
B-cv-cont-median	2712	2714	20
I-cv-cont-median	2714	2715	.
I-cv-cont-median	2715	2716	2
I-cv-cont-median	2717	2723	months
O	2724	2725	(
O	2725	2727	13
O	2727	2728	.
O	2728	2729	8
O	2729	2730	-
O	2730	2732	27
O	2732	2733	.
O	2733	2734	5
O	2734	2735	)
O	2736	2739	for
O	2740	2743	the
O	2744	2755	palbociclib
O	2756	2760	plus
O	2761	2770	letrozole
O	2771	2776	group
O	2777	2778	(
O	2778	2780	HR
O	2781	2782	0
O	2782	2783	.
O	2783	2786	488
O	2786	2787	,
O	2788	2790	95
O	2790	2791	%
O	2792	2794	CI
O	2795	2796	0
O	2796	2797	.
O	2797	2800	319
O	2800	2801	-
O	2801	2802	0
O	2802	2803	.
O	2803	2806	748
O	2806	2807	;
O	2808	2811	one
O	2811	2812	-
O	2812	2817	sided
O	2818	2819	p
O	2819	2820	=
O	2820	2821	0
O	2821	2822	.
O	2822	2826	0004
O	2826	2827	)
O	2827	2828	.

O	2829	2831	In
O	2832	2838	cohort
O	2839	2840	1
O	2841	2842	(
O	2842	2843	n
O	2843	2844	=
O	2844	2846	66
O	2846	2847	)
O	2847	2848	,
B-outcome	2849	2855	median
I-outcome	2856	2867	progression
I-outcome	2867	2868	-
I-outcome	2868	2872	free
I-outcome	2873	2881	survival
O	2882	2885	was
B-iv-cont-median	2886	2887	5
I-iv-cont-median	2887	2888	.
I-iv-cont-median	2888	2889	7
I-iv-cont-median	2890	2896	months
O	2897	2898	(
O	2898	2899	2
O	2899	2900	.
O	2900	2901	6
O	2901	2902	-
O	2902	2904	10
O	2904	2905	.
O	2905	2906	5
O	2906	2907	)
O	2908	2911	for
O	2912	2915	the
O	2916	2925	letrozole
O	2926	2931	group
O	2932	2935	and
B-cv-cont-median	2936	2938	26
I-cv-cont-median	2938	2939	.
I-cv-cont-median	2939	2940	1
I-cv-cont-median	2941	2947	months
O	2948	2949	(
O	2949	2951	11
O	2951	2952	.
O	2952	2953	2
O	2953	2954	-
O	2954	2957	not
O	2958	2967	estimable
O	2967	2968	)
O	2969	2972	for
O	2973	2976	the
O	2977	2988	palbociclib
O	2989	2993	plus
O	2994	3003	letrozole
O	3004	3009	group
O	3010	3011	(
O	3011	3013	HR
O	3014	3015	0
O	3015	3016	.
O	3016	3019	299
O	3019	3020	,
O	3021	3022	0
O	3022	3023	.
O	3023	3026	156
O	3026	3027	-
O	3027	3028	0
O	3028	3029	.
O	3029	3032	572
O	3032	3033	;
O	3034	3037	one
O	3037	3038	-
O	3038	3043	sided
O	3044	3045	p
O	3045	3046	<
O	3046	3047	0
O	3047	3048	.
O	3048	3052	0001
O	3052	3053	)
O	3053	3054	;
O	3055	3057	in
O	3058	3064	cohort
O	3065	3066	2
O	3067	3068	(
O	3068	3069	n
O	3069	3070	=
O	3070	3072	99
O	3072	3073	)
O	3073	3074	,
B-outcome	3075	3081	median
I-outcome	3082	3093	progression
I-outcome	3093	3094	-
I-outcome	3094	3098	free
I-outcome	3099	3107	survival
O	3108	3111	was
B-iv-cont-median	3112	3114	11
I-iv-cont-median	3114	3115	.
I-iv-cont-median	3115	3116	1
I-iv-cont-median	3117	3123	months
O	3124	3125	(
O	3125	3126	7
O	3126	3127	.
O	3127	3128	1
O	3128	3129	-
O	3129	3131	16
O	3131	3132	.
O	3132	3133	4
O	3133	3134	)
O	3135	3138	for
O	3139	3142	the
O	3143	3152	letrozole
O	3153	3158	group
O	3159	3162	and
B-cv-cont-median	3163	3165	18
I-cv-cont-median	3165	3166	.
I-cv-cont-median	3166	3167	1
I-cv-cont-median	3168	3174	months
O	3175	3176	(
O	3176	3178	13
O	3178	3179	.
O	3179	3180	1
O	3180	3181	-
O	3181	3183	27
O	3183	3184	.
O	3184	3185	5
O	3185	3186	)
O	3187	3190	for
O	3191	3194	the
O	3195	3206	palbociclib
O	3207	3211	plus
O	3212	3221	letrozole
O	3222	3227	group
O	3228	3229	(
O	3229	3231	HR
O	3232	3233	0
O	3233	3234	.
O	3234	3237	508
O	3237	3238	,
O	3239	3240	0
O	3240	3241	.
O	3241	3244	303
O	3244	3245	-
O	3245	3246	0
O	3246	3247	.
O	3247	3250	853
O	3250	3251	;
O	3252	3255	one
O	3255	3256	-
O	3256	3261	sided
O	3262	3263	p
O	3263	3264	=
O	3264	3265	0
O	3265	3266	.
O	3266	3270	0046
O	3270	3271	)
O	3271	3272	.

B-outcome	3273	3278	Grade
I-outcome	3279	3280	3
I-outcome	3280	3281	-
I-outcome	3281	3282	4
I-outcome	3283	3294	neutropenia
O	3295	3298	was
O	3299	3307	reported
O	3308	3310	in
B-iv-bin-abs	3311	3313	45
O	3314	3315	(
B-iv-bin-percent	3315	3317	54
I-iv-bin-percent	3317	3318	%
O	3318	3319	)
O	3320	3322	of
B-intervention-participants	3323	3325	83
O	3326	3334	patients
O	3335	3337	in
O	3338	3341	the
O	3342	3353	palbociclib
O	3354	3358	plus
O	3359	3368	letrozole
O	3369	3374	group
O	3375	3381	versus
B-cv-bin-abs	3382	3385	one
O	3386	3387	(
B-cv-bin-percent	3387	3388	1
I-cv-bin-percent	3388	3389	%
O	3389	3390	)
O	3391	3393	of
B-control-participants	3394	3396	77
O	3397	3405	patients
O	3406	3408	in
O	3409	3412	the
O	3413	3422	letrozole
O	3423	3428	group
O	3428	3429	,
B-outcome	3430	3440	leucopenia
O	3441	3443	in
B-iv-bin-abs	3444	3446	16
O	3447	3448	(
B-iv-bin-percent	3448	3450	19
I-iv-bin-percent	3450	3451	%
O	3451	3452	)
O	3453	3459	versus
B-cv-bin-abs	3460	3464	none
O	3464	3465	,
O	3466	3469	and
B-outcome	3470	3477	fatigue
O	3478	3480	in
B-iv-bin-abs	3481	3485	four
O	3486	3487	(
B-iv-bin-percent	3487	3488	4
I-iv-bin-percent	3488	3489	%
O	3489	3490	)
O	3491	3497	versus
B-cv-bin-abs	3498	3501	one
O	3502	3503	(
B-cv-bin-percent	3503	3504	1
I-cv-bin-percent	3504	3505	%
O	3505	3506	)
O	3506	3507	.

B-outcome	3508	3515	Serious
I-outcome	3516	3523	adverse
I-outcome	3524	3530	events
O	3531	3535	that
O	3536	3544	occurred
O	3545	3547	in
O	3548	3552	more
O	3553	3557	than
O	3558	3561	one
O	3562	3569	patient
O	3570	3572	in
O	3573	3576	the
O	3577	3588	palbociclib
O	3589	3593	plus
O	3594	3603	letrozole
O	3604	3609	group
O	3610	3614	were
B-outcome	3615	3624	pulmonary
I-outcome	3625	3633	embolism
O	3634	3635	(
B-iv-bin-abs	3635	3640	three
O	3641	3642	[
B-iv-bin-percent	3642	3643	4
I-iv-bin-percent	3643	3644	%
O	3644	3645	]
O	3646	3654	patients
O	3654	3655	)
O	3655	3656	,
B-outcome	3657	3661	back
I-outcome	3662	3666	pain
O	3667	3668	(
B-iv-bin-abs	3668	3671	two
O	3672	3673	[
B-iv-bin-percent	3673	3674	2
I-iv-bin-percent	3674	3675	%
O	3675	3676	]
O	3676	3677	)
O	3677	3678	,
O	3679	3682	and
B-outcome	3683	3692	diarrhoea
O	3693	3694	(
B-iv-bin-abs	3694	3697	two
O	3698	3699	[
B-iv-bin-percent	3699	3700	2
I-iv-bin-percent	3700	3701	%
O	3701	3702	]
O	3702	3703	)
O	3703	3704	.

O	3705	3707	No
O	3708	3713	cases
O	3714	3716	of
B-outcome	3717	3724	febrile
I-outcome	3725	3736	neutropenia
I-outcome	3737	3739	or
I-outcome	3740	3751	neutropenia
I-outcome	3751	3752	-
I-outcome	3752	3759	related
I-outcome	3760	3770	infections
O	3771	3775	were
O	3776	3784	reported
O	3785	3791	during
O	3792	3795	the
O	3796	3801	study
O	3801	3802	.

B-iv-bin-abs	3803	3805	11
O	3806	3807	(
B-iv-bin-percent	3807	3809	13
I-iv-bin-percent	3809	3810	%
O	3810	3811	)
O	3812	3820	patients
O	3821	3823	in
O	3824	3827	the
O	3828	3839	palbociclib
O	3840	3844	plus
O	3845	3854	letrozole
O	3855	3860	group
O	3861	3864	and
B-cv-bin-abs	3865	3868	two
O	3869	3870	(
B-cv-bin-percent	3870	3871	2
I-cv-bin-percent	3871	3872	%
O	3872	3873	)
O	3874	3876	in
O	3877	3880	the
O	3881	3890	letrozole
O	3891	3896	group
B-outcome	3897	3909	discontinued
O	3910	3913	the
O	3914	3919	study
O	3920	3927	because
O	3928	3930	of
O	3931	3938	adverse
O	3939	3945	events
O	3945	3946	.

O	3947	3950	The
O	3951	3959	addition
O	3960	3962	of
O	3963	3974	palbociclib
O	3975	3977	to
O	3978	3987	letrozole
O	3988	3990	in
O	3991	3995	this
O	3996	4001	phase
O	4002	4003	2
O	4004	4009	study
O	4010	4023	significantly
O	4024	4032	improved
O	4033	4044	progression
O	4044	4045	-
O	4045	4049	free
O	4050	4058	survival
O	4059	4061	in
O	4062	4067	women
O	4068	4072	with
O	4073	4081	advanced
O	4082	4091	oestrogen
O	4092	4100	receptor
O	4100	4101	-
O	4101	4109	positive
O	4110	4113	and
O	4114	4118	HER2
O	4118	4119	-
O	4119	4127	negative
O	4128	4134	breast
O	4135	4141	cancer
O	4141	4142	.

O	4143	4144	A
O	4145	4150	phase
O	4151	4152	3
O	4153	4158	trial
O	4159	4161	is
O	4162	4171	currently
O	4172	4180	underway
O	4180	4181	.

O	4182	4188	Pfizer
O	4188	4189	.
